Ph.D., SVP, BD and Marketing, Personalis
Biography
Stephane leads the Business Development & Marketing team at Personalis. Previously, Stephane was at Illumina where he led Illumina’s companion diagnostic partnerships with pharmaceutical companies in oncology, the international expansion of NIPT (Non Invasive Prenatal Testing) and Illumina’s venture investments in start-ups such as Twist (synthetic biology) and Boreal Genomics (liquid biopsy), for which he served as Illumina-appointed board observer. Prior to Illumina, Stephane was at Caliper Lifesciences for 15 years. He developed and launched several microfluidic DNA and protein testing products that became standards in genomic laboratories today, and he led corporate development for Caliper. Stephane holds a Ph.D. in Analytical Chemistry from the University of Wisconsin, Madison and a Master’s degree in Chemical Engineering from Strasbourg University, France.
Talk
NeXT Personal: The Next Generation in MRD Testing for Solid Tumors
Session Abstract – PMWC 2022 Silicon Valley
The analysis of blood for circulating tumor cells (CTC), circulating tumor DNA (ctDNA), extracellular vesicles, or more recently, tumor-educated platelets has opened new avenues for cancer diagnostics, including early detection of tumors, improved risk assessment and staging, as well as early detection of relapse to improve patient care. The track will introduce the up-to-date technologies used in liquid biopsy and review the clinical utilities in cancer screening, detection of minimal residual diseases, selection of molecular-targeted drugs, as well as monitoring of treatment responsiveness.
Sessions:
- Early Cancer Detection- Status quo, Technical and Clinical Challenges, and the Future (PANEL)
Session Chair: Jimmy Lin, Freenome
- Peter Bach, Delfi Diagnostics
- Ash Alizadeh, Stanford
- Amir Ali Talasaz, Guardant Health
- Anne-Renee Hartman, Adela
- How is Liquid Biopsy Changing the Testing Paradigm for Oncology Patients? (PANEL)
Session Chair: Rebecca Brandes, Agilent
- Edward Abrahams, PMC
- Blandine Merino, Agilent
- Adrian Lee, UPMC - The Emerging Role of ctDNA for Molecular Residual Disease (MRD) Assessment and Recurrence Monitoring
- Minetta Liu, Natera - Liquid Biopsy for Screening, Diagnosis, Prognosis and Therapy Guidance
Session Chair: Sam Salman, miR Scientific
- Frederick Baehner, Exact Sciences
- The Advantages of Exosomes as a Liquid Biopsy Based Markers
Session Chair: Johan Skog, Exosome Diagnostics
- Jamil Azzi, Harvard
- Dolores Di Vizio, Cedars-Sinai Medical Center
- Showcase
- Dave Mullarkey, Bluestar Genomics
- Stephane Mouradian, Personalis
- Michael Dugan, Biocept
- Priti Hegde, Foundation Medicine
- Steven Soper, The University of Kansas
- Maggie Rougier-Chapman, Personal Genome Diagnostics
- Daniel Kim, UCSC
